Yunnan Baiyao Group (000538.SZ) stated on the investor interaction platform that the company is conducting secondary development work on Gongxuening Capsules, Qixuekang, and Yunnan Baiyao Capsules. In 2023, the clinical observation study project of Gongxuening Capsules for the treatment of uterine bleeding completed 1791 cases, and it is expected to obtain a clinical trial report by the end of 2024. The secondary development of Qixuekang, which is used to improve various discomfort symptoms such as blood stasis in patients, has been completed. The clinical study project for improving heart and vascular health has completed 70% of patient enrollment, and some of the results that have been exited were statistically analyzed, showing preliminary evidence of improving vascular health. It is expected to obtain a clinical trial report by the end of 2024. The secondary development of Yunnan Baiyao Capsules, actively promoting clinical research on bone healing promotion, wound healing treatment of Yunnan Baiyao, and exploring the safety and effectiveness of Yunnan Baiyao in various fields of evidence-based medicine in dental and digestive departments.
云南白药(000538.SZ)：正在开展宫血宁胶囊、气血康、云南白药胶囊的二次开发工作
Yunnan Baiyao Group (000538.SZ): is conducting second-phase development work on Gongxue Ning Capsules, Qixue Kang, and Yunnan Baiyao Capsules.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.